Acute Coronary Syndrome (ACS)
Conditions
Interventions
A total of 1600 patients with acute coronary syndrome were enrolled in this study, including 800 patients with comorbid diabetes and 800 patients without diabetes.:None
Sponsors
The Second Xiangya Hospital, Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Aged between 18 and 80 years, regardless of sex; (2) Patients diagnosed with acute coronary syndrome (ACS) within 7 days of symptom onset, including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation acute coronary syndrome (NSTE-ACS); (3) Diabetes was defined as the presence of any of the following conditions: a self-reported history of diabetes, a fasting plasma glucose level >= 7.0 mmol/L (126 mg/dL), a fasting plasma hemoglobin A1c (HbA1c) level >= 6.5%, or current use of oral hypoglycemic agents or insulin therapy. (4) Provision of written informed consent by the patient or their legal guardian prior to enrollment; (5) After hospital admission and prior to sample collection, participants must refrain from vigorous physical activity for 24 hours and rest in a seated position for at least 5 minutes before blood draw.
Exclusion criteria
Exclusion criteria: (1) Patients with stable coronary artery disease, primary cardiomyopathy, valvular heart disease, or other severe cardiac conditions; (2) Those with systemic wasting diseases such as malignant tumors or tuberculosis; (3) Individuals who have experienced severe trauma or major surgery; (4) Patients in poor general condition or with end-stage organ failure; (5) Inability to obtain blood samples; (6) Patients unable to comprehend the study content and therefore unable to cooperate, or those who refuse to provide written informed consent; (7) Women who are pregnant or lactating.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major adverse cardiovascular events (MACE), defined as a composite of sudden cardiac death, heart failure-related death, stroke-related death, and secondary endpoints including hospitalization for heart failure, hospitalization for stroke, and the occurrence of spontaneous sustained ventricular tachycardia (VT) or hospitalization due to appropriate implantable cardioverter-defibrillator (ICD) therapy.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum angiopoietin-like protein 8 (ANGPLT8), cardiac enzymes, N-terminal pro-B-type natriuretic peptide (NT-proBNP), blood lipids, hemoglobin A1c (HbA1c), random blood glucose, estimated glomerular filtration rate (eGFR), high-sensitivity C-reactive protein (hs-CRP).;Left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), and left ventricular end-systolic volume (LVESV).; | — |
Countries
China
Contacts
Public ContactYu Bilian
The Second Xiangya Hospital, Central South University
Outcome results
None listed